Search Medical Condition
Please enter condition
Please choose location

Antiphospholipid Syndrome Clinical Trials

A listing of Antiphospholipid Syndrome medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (14) clinical trials

Apixaban for the Secondary Prevention of Thromboembolism Among Patients With the AntiphosPholipid Syndrome

This pilot study has two primary aims. The first is to identify patients with a clinical diagnosis of APS and then describe their recruitment, enrollment, screening failure rate, adherence to therapy, clinical characteristics, and APS diagnostic criteria in terms of broadly accepted published standards. Essential in this aim is capture ...

Phase

Genetic Risk Factors Associated With Antiphospholipid Antibody Syndrome

APS is an autoimmune disorder that causes an increased risk for developing a venous or arterial thromboembolism, as well as recurrent miscarriages. APS frequently occurs in people with lupus, and is referred to as secondary APS in this case. Many people who have APS, however, do not have another autoimmune ...

Phase N/A

Register for Pediatric Patients With Antiphospholipid Syndrome (APS): European Project Extended Internationally Study

The purpose of this study is to gather information about causes and treatment of Antiphospholipid Syndrome.

Phase N/A

AntiPhospholipid Syndrome Low-molecular-weight Heparin Pregnancy Loss Evaluation: The Pilot Study

The purpose of this pilot trial is to determine the feasibility of conducting a multicenter randomized full trial evaluating antepartum prophylaxis with ASA versus LMWH/ASA in women with confirmed APS and a history of late or recurrent early pregnancy loss. Given the large sample size needed to adequately power a ...

Phase N/A

Longitudinal Study of the Clinical and Haematological Cause of Women With Antiphospholipid Antibodies.

The association between APA and thrombosis is well documented. Both LA and ACA are often detected in individuals with SLE but there is no prospective data on the risk of thrombosis in women who present with recurrent miscarriages in association with APA. This study should significantly advance medical knowledge of ...

Phase N/A

Predictors of Pregnancy Outcome in Systemic Lupus Erythematosus (SLE) and Antiphospholipid Syndrome (APS)

Thrombosis and pregnancy loss are common features of systemic lupus erythematosus (SLE), particularly in the presence of antiphospholipid (aPL) antibodies. The in vivo mechanisms by which aPL antibodies lead to vascular events and, specifically, to recurrent fetal loss are largely unknown. Studies in a mouse model of antiphospholipid antibody syndrome ...

Phase N/A

Pregnancy and Medically Assisted Conception in Rare Diseases

Rare diseases frequently affect women of childbearing age. Pregnancy in these women has become less rare, but remains associated with high levels of complications. One obstacle to their optimal management during pregnancy is that there are no prospective studies of pregnancy during rare diseases and several connective tissue diseases. As ...

Phase N/A

Phenomics in Autoimmune and Inflammatory Diseases

The family of inflammatory/autoimmune systemic diseases (IAD) represents a large group of human diseases. For most if not all of these IAD, the pathophysiological processes or exact causes remain poorly understood. Progresses in molecular understanding of these IAD have led to realize that these are not two distinct categories of ...

Phase N/A

Ankylosing Spondylitis and Antiphospholipid Antibodies

Methods Experimental design: longitudinal study prospective in a single center. The Ankylosing Spondylitis Assesment Study (ASAS) criteria are: (1) age <45 years, back pain 3 months, sacroiliitis on imaging and 1 associated minor criterion, or (2) HLA B27 positive and 2 minor criteria. Minor criteria are: inflammatory back pain, arthritis, ...

Phase N/A

Rivaroxaban in Thrombotic Antiphospholipid Syndrome

Primary Study Objective(s) The primary objective is to demonstrate the non-inferiority of Rivaroxaban 20 mg (or 15mgqd in case of moderate renal insufficiency) versus warfarin (INR 2.0-3.0) with respect to the occurrence of the cumulative end point of incident acute thrombosis (arterial or venous) confirmed by appropriate imaging studies, major ...

Phase